Claim 1: a method for Increasing the survival or progression free survival in a patient who has a solid tumor characterized by the patients have elevated Serum levels of c-reactive Protein (CRP), which comprises administering a jak inhibitor or a inhibi Dor Signalling of il-6 to the patient,Where the Administration increases Survival or progression free survival of the patient. The Method of claim 19: any of claims 1 to 18, characterized by the inhibitor of jak is ruxolitinib or a pharmaceutically acceptable Salt thereof.The Method of claim 21: any of claims 1 to 20 characterized in that the method comprises administering to a patient in one or more additional chemotherapeutic agents. The Method of claim 24: 21 The demand characterized by the additional chemotherapeutic agents are capecitabine.The Method of Claim: the claim 51 48 characterized by the selective inhibitor of JAK1 is 4 - [3 - (cyanomethyl) - 3 - (3,5 - dimethyl - 1H, 1H - 4.4 - bipirazol - 1 - il) azetidin - 1 - 2.5 - difluoro - yl] - N - [(1S) 2,2,2-trifluoro-1 - methylethyl] benzamide or a pharmaceutically acceptable Salt thereof.The Method of Claim: the claim 52 48 characterized by the selective inhibitor of JAK1 is {1 - {[1 - 3 - fluoro - 2 - (trifluoromethyl) isonicotinoil piperidin-4-yl il}] - 3 - [4 - (7H pyrrolo [2,3-d] pyrimidin-4-yl) - 1H pyrazol-1-yl] azetidin - il - 3} or a pharmaceutically acceptable Salt of acetonitrile This.Reivindicación 1: Un método para aumentar la supervivencia o la supervivencia sin evolución en un paciente que tiene un tumor sólido caracterizado por que el paciente tiene concentraciones séricas elevadas de proteína C reactiva (CRP), que comprende administrar un inhibidor de JAK o un inhibidor de señalización de IL-6 al paciente, en donde la administración aumenta la supervivencia o la supervivencia sin evolución del paciente. Reivindicación 19: El método de cualquiera de las reivindicaciones de 1 a 18 caracterizado por que el inhibidor de JAK es ruxolitinib o una s
